Bisphosphonates vs. Atypical Femur Fractures - Influence on Bone Resorption

Abstract:

Bisphosphonates currently represent the main therapy in the fight against osteoporosis. This is a serious condition, with an increasing incidence, presently affecting about 12 million people in the U.S. mostly women aged over 50 years. Thus, approximately 40% -50% of them suffer an osteoporotic fracture. Bisphosphonates mechanism of action consists in reducing osteoclast-mediated bone resorption, modifying bone turn over, leading to an increase in bone density. This dramatically reduces the risk of fracture. Although bisphosphonates shows a good safety profile, lately emerged some alarm signals that link their long management to some unusual side effects. Bisphosphonates is an effective therapy to combat osteoporosis, their causal relationship with FAF production not being shown. In the absence of other evidence, it is unclear whether BF therapy is directly involved in producing FAF or only a component of a combination of factors, in reality being just an indicator of a severe degree of osteoporosis. In the same time, we must not forget that the FAF are very rare compared to the number of patients in therapy with BF and the number of typical femur fractures, and the risk / benefit ratio it is definitely in favor of the benefit.

• Periodical: Key Engineering Materials (Volume 638)
• Pages: 296-300
• DOI: https://doi.org/10.4028/www.scientific.net/KEM.638.296
• Online since: March 2015
• Authors: Razvan Adam*, Carmen Orban, Nicolae Gheorghiu, Horia Orban, Iulian Antoniac
• Keywords: Bisphosphonates, Bone, Fracture, Resorbtion

References

[1] Odvina C.V., Zerwekh J.E., Rao D.S., Maalouf N., Gottschalk F.A., Pak C.Y. (2005) Severely suppressed bone turnover: A potential complication of alendronate therapy. J ClinEndocrinolMetab 90: 1294–1301.

DOI: 10.1210/jc.2004-0952

[2] Goh S.K., Yang K.Y., Koh J.S.B., Wong M.K., Chua S.Y., Chua D.T.C., Howe T.S. (2007) Subtrochanteric insufficiency fractures in patients on alendronate therapy: A Caution. J Bone Joint Surg Br 3: 349–353.

DOI: 10.1302/0301-620x.89b3.18146

[3] Barclay, Laurie. et. al. Long-Term Use of Bisphosphonates Increases Risk for Atypical Fractures. Medscape Medical News. WebMD Health Professional Network, March 01, (2011).

[4] Neviaser A.S., Lane J.M., Lenart B.A., Edobor-Osula F., Lorich D.G. (2008) Low-energy femoral shaft fractures associated with alendronate use. J Orthop Trauma 22: 346–350.

DOI: 10.1097/bot.0b013e318172841c

[5] Lenart B.A., Lorich D.G., Lane J.M. (2008) Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate. N Engl J Med 358: 1304–1306.

DOI: 10.1056/nejmc0707493

[6] Fei-Yuan Hsiao, Weng-FoungHuang, Yi-Ming Chen, Yu-Wen Wen, PhD; (November 2011) Hip and Subtrochanteric or Diaphyseal Femoral Fractures in Alendronate Users: A 10-Year, Nationwide Retrospective Cohort Study in Taiwanese Women; Clinical Therapeutics, Volume 33, Issue 11, Pages 1659–1667.

DOI: 10.1016/j.clinthera.2011.09.006

[7] Abrahamsen B., Eiken P., Eastell R. (2009) Subtrochanteric and diaphyseal femur fractures in patients treated with alendronate: A register-based national cohort study. J Bone Miner Res 24: 1095–1102.

DOI: 10.1359/jbmr.081247

[8] Schilcher J., Michaëlsson K., Aspenber P. (2011) Bisphosphonate use and atypical fractures of the femoral shaft. N Engl J Med 364: 1728–1737.

DOI: 10.1056/nejmoa1010650

[9] Giusti A., Hamdy N.A.T., Dekkers O.M., Ramautar S.R., Dijkstra S., Papapoulos S.E. (2011).

[10] Park-Wyllie LY, Mamdani MM, Juurlink DN, Hawker GA, Gunraj N, Austin PC., et al. (2011) Bisphosphonate use and the risk of subtrochanteric or femoral shaft fractures in older women. JAMA 305(8): 783–789.

DOI: 10.1001/jama.2011.190

[11] Shane E., Burr D., Ebeling P.R., Abrahamsen B., Adler R.A., Brown T.D., et al. (2010).